Brentuximab Vedotin in Patients Aged 60 Years or Older with Relapsed or Refractory CD30+ Lymphomas: A Retrospective Evaluation of Safety and Efficacy.

Publication Type:

Journal Article


Leukemia & lymphoma (2013)


2013, Clinical Research Division, January 2014


Abstract Older adults comprise a significant proportion of the cancer population, but are under-represented in clinical trials. We conducted a retrospective analysis of the safety and efficacy of brentuximab vedotin in adults ≥60 years with relapsed CD30-positive lymphomas. Baseline characteristics and safety data were compared for older (median age 66) and younger patients (<60 years, median age 32). Exposure to brentuximab vedotin was comparable. Older patients had more pre-existing conditions (median 11 vs 6) and were receiving more concomitant medications (median 7.5 vs 4). Higher rates of anemia (30% vs 10%), peripheral sensory neuropathy (60% vs 46%), fatigue (58% vs 43%), and adverse events ≥ Grade 3 (70% vs 56%) occurred in older patients. Objective response rates were 56% and 100% in older Hodgkin lymphoma and systemic anaplastic large cell lymphoma patients, respectively. With appropriate monitoring, brentuximab vedotin may represent a meaningful clinical option for older patients with relapsed CD30-positive lymphomas.